MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

0026-895X/04/6603-627-634$20.00
Mol Pharmacol 66:627-634, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bendetz-Nezer, S.
Right arrow Articles by Priel, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bendetz-Nezer, S.
Right arrow Articles by Priel, E.

DNA Topoisomerase I As One of the Cellular Targets of Certain Tyrphostin Derivatives

Sarit Bendetz-Nezer, Aviv Gazit, and Esther Priel

Department of Immunology and Microbiology, Faculty of Health Sciences, the Ben-Gurion University Cancer Research Center, Ben-Gurion University Beer-Sheva, Israel (S.B.-N., E.P.); and Department of Organic Chemistry, the Hebrew University, Jerusalem, Israel (A.G.)

DNA topoisomerases (topo) are the cellular targets of several anticancer drugs used today in the clinic. Our previous work demonstrated that certain tyrphostin derivatives, known as protein tyrosine kinase antagonists, are catalytic inhibitors of DNA topoisomerases I (topo I) in vitro. In this study, we examined the ability of tyrphostin derivatives to affect the activity of topo I in the cell (in vivo) and determined their in vivo mode of action. Two approaches were used; in the first, we examined the direct effect of the treatment of tumor cells with tyrphostins on the activity, level, and post-translational modifications of the cellular topo I. The second approach was to determine the influence of pretreatment of tumor cells with tyrphostin on the cellular induced effects of camptothecin (CPT), a known inhibitor of topo I. The results show that treatment of fibrosarcoma cells with tyrphostin inhibited the DNA relaxation activity of topo I but did not reduce the level of topo I protein. Tyrphostin treatments caused conformational changes of the cellular topo I probably by binding to the enzyme. Pretreatment of the cells with tyrphostin before CPT prevented the CPT-induced degradation of topo I and reduced the enzyme-DNA cleavable complexes and the ubiquitination/sumoylation of the enzyme. These data suggest that topo I is one of the cellular targets of tyrphostin and that this drug acts in vivo (in the cell) as a catalytic inhibitor of the enzyme that alters the binding of the enzyme to the DNA.

Received January 16, 2004; accepted June 4, 2004

Address correspondence to: E. Priel, Dept. Microbiology and Immunology, Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva 81405, Israel. E-mail: priel{at}bgumail.bgu.ac.il




This article has been cited by other articles:


Home page
 GlycobiologyHome page
N. Noach, Y. Segev, I. Levi, S. Segal, and E. Priel
Modification of Topoisomerase I Activity by Glucose and by O-Glcnacylation of the Enzyme Protein
Glycobiology, December 1, 2007; 17(12): 1357 - 1364.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
I. Har-Vardi, R. Mali, M. Breietman, Y. Sonin, S. Albotiano, E. Levitas, G. Potashnik, and E. Priel
DNA topoisomerases I and II in human mature sperm cells: characterization and unique properties
Hum. Reprod., August 1, 2007; 22(8): 2183 - 2189.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics